TabBO: A model reflecting common molecular features of androgen- independent prostate cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1190-1197

  Navone, Nora M ^a,b   Rodriguez Vargas, Maria Del C ^a   Benedict, William F ^a   Troncoso, Patricia ^a   McDonnell, Timothy J ^a   Zhou, Jaim Hua ^a   Luthra, Rajyalakshmi ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GROWTH; GENE MUTATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANDROGENS; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MODELS, BIOLOGICAL; MUTATION; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; SEQUENCE ANALYSIS, DNA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034114781     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Navone, N. M., Olive, M., Ozen, M., Davis, R., Troncoso, P., Tu, S-M., Johnston, D., Pollack, A., Pathak, S., von Eschenbach, A. C., and Logothetis, C. J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res., 3: 2493-2500, 1997.
2. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W., Hsieh, J. T., Tu, S. M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6945, 1992.
3. McDonnell, T. J., Navone, N. M., Troncoso, P., Pisters, L., Conti, C. J., von Eschenbach, A. C., Brisbay, S., and Logothetis, C. J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol., 157: 569-574, 1997.
4. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role of p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
5. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschebach, A. C., and Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657-1669, 1993.
6. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z. F., Fuks, Z., and Cordon-Cardo, C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276-1280, 1994.
7. Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1: 1111-1118, 1995.
8. Raffo, A. J., Perlman, H., Chen, M. W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
9. Westin, P., Lo, P., Marin, M. C., Fernandez, A., Sarkiss, M., Tu, S-M., Brisbay, S. M., von Eschenbach, A. C., and McDonnell, T. J. bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. Int. J Oncol., 10: 113-118, 1997.
10. Beham, A. W., Brisbay, S., Sarkiss, M., Tu, S. M., von Eschenbach, A. C., and McDonnell, T. J. Molecular correlates of Bcl-2 enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. Int. J. Mol. Med., 1: 953-959, 1998.
11. Xu, H-J., Hu, S-M., Hashimoto, T., Takahashi, R., and Benedict, W. F. The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. Oncogene, 4: 807-812, 1989.
12. Li, J., Hu, S. X., Perng, G. S., Zhou, Y., Xu, K., Zhang, C., Seigne, J., Benedict, W. F., and Xu, H. J. Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene, 13: 2379-2386, 1996.
13. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
14. Van Meir, E. G., Kikuchi, T., Tada, M., Li, H., Diserens, A-C., Wojcik, B. E., Huang, H-J. S., Friedmann, T., de Tribolet, N., and Cavenee, W. K. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54: 649-652, 1994.
15. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991.
16. Carroll, A. G., Voeller, J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate., 23: 123-134, 1993.
17. Papandreou, C. N., Bogenrieder, T., Scher, H. I., Albino, A. P., and Nanus, D. M. Expression and sequence analysis of the SDI1/WAF1/ CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int. J. Oncol., 8: 1237-1241, 1996.
18. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
19. Haldar, S., Negrini, M., Monne, M., Sabbioni, S., and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cell. Cancer Res., 54: 2095-2097, 1994.
20. Ranpino, N., Yamamoto, H., Jonov, Y., Li, Y., Sawai, H., Reed, J. C., and Perucho, M. Somatic mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype. Science (Washington DC)., 275: 967-969, 1997.
21. Evans, S. C., Mims, B., McMasters, K. M., Foster, C. J., deAndrade, M., Amos, C. I., Strong, L. C., and Lozano, G. Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum. Genet., 102: 681-686, 1998.
22. Ara, S., Lee, P. S. Y., Hansen, M. F., and Saya, H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res., 18: 4961, 1990.
23. Gao, X., Chen, Y. Q., Wu, N., Grignon, D. J., Sakr, W., Porter, A. T., and Honn, K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene., 11: 1395-1398, 1995.
24. Tilley, W. D., Buchanan, G., Hickey, T. E., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277-285, 1996.
25. Peterziel, H., Culig, Z., Stober, J., Hobisch, A., Radmayr, C., Bartsch, G., Klocker, H., and Cato, A. C. B. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int. J. Cancer., 63: 544-550, 1995.
26. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
27. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
28. Kleinerman, D. I., Troncoso, P., Pisters, L. L., Navone, N. M., Hsieh, J-T., Logothetis, C. J., and von Eschenbach, A. C. Expression and structure of the androgen receptor in bone metastases of hormone refractor prostate cancer. J. Urol., 155: 624A, 1996.
29. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am. J. Pathol., 146: 1567-1576, 1996.
30. Gittes, R. F. Carcinoma of the prostate. N. Eng. J. Med., 324: 236-245, 1991.
31. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med., 331: 996-1004, 1994.
32. Kyprianou, N., Martikainen, P., Davis, L., English, H. F., and Isaacs, J. T. Programmed cell death as a new target for prostatic cancer therapy. In: J. T. Isaacs (ed.), Prostate Cancer Cell and Molecular Mechanisms in diagnosis and treatment, Vol. 11, pp. 265-277. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1991.
33. Koivisto, P., Hyytinen, E., Palmberg, C., Tammela, T., Visakorpi, T., Isola, J., and Kailioniemi, O. P. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol., 147: 1608-1614, 1995.
34. Rosse, T., Olivier, R., Monney, L., Rager. M., Conus, S., Fellay, I., Jansen, B., and Borner, C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome C. Nature (Lond.)., 391: 496-499, 1998.
35. Yin, C., Knudsen, C. M., and Krosmeyer, S. J., Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature (Lond.)., 385: 637-640, 1997.
36. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell., 88: 323-331, 1997.
37. Rowan, S., Ludwing, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., and Vousden, K. H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J., 15: 827-838, 1996.
38. Bates, S., and Vousden, K. H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev., 6: 12-19, 1996.